Gerassimos A Pangalis
Gerassimos A Pangalis is an expert in Hematology at Athens Medical Center (Greece). As of July 2026, ScienceLeadR ranks Gerassimos A Pangalis in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders, and in the top 1% of experts in Greece for Leukemia. Gerassimos A Pangalis has authored 323 publications, the most recent in 2026. SLR score: 1,020 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1987 - 2026
Number : 323
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Clonal B-Cell Lymphocytosis of Marginal Zone Origin: Presenting Features, Clinical Evolution and Prognostic Factors. PMID 42449567 — cells, lymphocytosis, therapeutics, lymphoproliferative disorders, mutation, b-lymphocytes, prognosis, cytopenia | Cancers (Basel) | 2026 | 0 |
| Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in Greece. PMID 42397568 — hematology, hematologic neoplasms, retrospective studies, neoplasms, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, rituximab, therapeutics, genes, mos | Ann Hematol | 2026 | 0 |
| Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance. PMID 42200578 — cells, lymphoma, multiple chronic conditions, therapeutics, mutation, hematologic diseases | Blood Adv | 2026 | 0 |
| Focus on Extremely Late Relapses in Hodgkin Lymphoma: A Single Center Analysis. PMID 41827712 — cells, incidence, hodgkin disease, lymphoma, drug therapy, diagnosis, therapeutics, chemotherapy | Cancers (Basel) | 2026 | 0 |
| Unusual Clinical Presentation of B-Cell Prolymphocytic Leukemia Cases as Splenic Marginal Zone Lymphoma Effectively Treated With Rituximab Monotherapy. PMID 40750426 — cells, blood, lymphoma, classification, leukemia, leukemia, prolymphocytic, b-cell, rituximab, therapeutics, medical oncology, leukemia, prolymphocytic, b-lymphocytes | Anticancer Res | 2025 | 0 |
LeadR Networks
Main global connection map